Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Abivax

Market Cap 7.04B 8.1B 6.47B 6.09B 11.41B 769B 11.54B 76.95B 29.86B 376B 30.38B 29.72B 1,300B P/E 2026 *
-23x
P/E 2027 * -25.5x
Enterprise Value 6.55B 7.54B 6.03B 5.67B 10.63B 716B 10.75B 71.65B 27.8B 350B 28.29B 27.68B 1,211B EV / Sales 2026 *
1,745x
EV / Sales 2027 * 72.7x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day+5.69%
1 week+2.91%
Current month-22.13%
1 month-10.85%
3 months-17.63%
6 months-6.16%
Current year-26.66%
1 week 80.7
Extreme 80.7
89.55
1 month 60.45
Extreme 60.45
118.6
Current year 60.45
Extreme 60.45
132
1 year 5.12
Extreme 5.12
132
3 years 4.51
Extreme 4.51
132
5 years 4.51
Extreme 4.51
132
10 years 3.87
Extreme 3.87
132
Manager TitleAgeSince
Chief Executive Officer 68 05/05/2023
Director of Finance/CFO - 02/01/2017
Chief Tech/Sci/R&D Officer - 19/03/2026
Director TitleAgeSince
Chairman 65 15/07/2024
Director/Board Member 58 11/07/2023
Chairman 68 05/05/2023
Date Insider Type Main position Quantity % Market Cap.
05-21Fiscal year

Chief Executive Officer

35,456 0.0445%
03-23Fiscal year

Chief Executive Officer

35,456 0.0448%
02-20Free

Director

2,471 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+5.69%+2.91%+1,449.12%+455.35% 7.73B
-0.22%-0.40%-13.00%-13.09% 43.51B
+0.76%+5.50%+296.71%+540.82% 33.29B
-0.47%-2.05%-0.66%+31.20% 29.34B
-4.74%-8.37%+7.17%-20.99% 29.9B
+0.06%+2.71%+13.31%+21.11% 25.42B
-0.02%+8.40% - - 14.36B
-0.98%-2.08%+51.87%+106.06% 13.18B
-0.29%-3.76%+2.12%+1.69% 12.72B
+1.67%-0.36%+110.87%+81.16% 12.08B
Average +0.15%+0.34%+213.06%+133.70% 22.15B
Weighted average by Cap. -0.41%+0.61%+111.46%+116.70%

Financials

2026 *2027 *
Net sales 3.75M 4.32M 3.45M 3.25M 6.09M 410M 6.16M 41.06M 15.93M 201M 16.21M 15.86M 694M 90.1M 104M 82.89M 77.95M 146M 9.84B 148M 985M 382M 4.81B 389M 381M 16.65B
Net income -267M -307M -246M -231M -433M -29.16B -438M -2.92B -1.13B -14.25B -1.15B -1.13B -49.32B -215M -247M -198M -186M -349M -23.49B -353M -2.35B -912M -11.48B -928M -908M -39.73B
Net Debt -484M -557M -446M -419M -786M -52.93B -795M -5.3B -2.06B -25.87B -2.09B -2.05B -89.52B -483M -555M -444M -418M -783M -52.74B -792M -5.28B -2.05B -25.78B -2.08B -2.04B -89.21B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
17/06/26 88.30 +5.69% 210,039
16/06/26 83.55 -1.82% 134,842
15/06/26 85.10 +0.06% 219,130
12/06/26 85.05 -0.12% 116,959
11/06/26 85.15 +1.25% 195,790
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
88.30EUR
Average target price
108.40EUR
Spread / Average Target
+22.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!